{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:56:57Z","timestamp":1774288617082,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012399","name":"U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201600005I"],"award-info":[{"award-number":["HHSO100201600005I"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that partly evade neutralizing antibodies raises concerns of reduced vaccine effectiveness and increased infection. We previously demonstrated that the SARS-CoV-2 spike protein vaccine adjuvanted with AS03 (CoV2 preS dTM-AS03) elicits robust neutralizing antibody responses in na\u00efve subjects. Here we show that, in macaques primed with mRNA or protein-based subunit vaccine candidates, one booster dose of CoV2 preS dTM-AS03 (monovalent D614 or B.1.351, or bivalent D614\u2009+\u2009B.1.351 formulations), significantly boosts the pre-existing neutralizing antibodies against the parental strain from 177- to 370-fold. Importantly, the booster dose elicits high and persistent cross-neutralizing antibodies covering five former or current SARS-CoV-2 variants of concern (Alpha, Beta, Gamma, Delta and Omicron) and, unexpectedly, SARS-CoV-1. Interestingly, we show that the booster specifically increases the functional antibody responses as compared to the receptor binding domain (RBD)-specific responses. Our findings show that these vaccine candidates, when used as a booster, have the potential to offer cross-protection against a broad spectrum of variants. This has important implications for vaccine control of SARS-CoV-2 variants of concern and informs on the benefit of a booster with the vaccine candidates currently under evaluation in clinical trials.<\/jats:p>","DOI":"10.1038\/s41467-022-29219-2","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T06:04:10Z","timestamp":1648706650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates"],"prefix":"10.1038","volume":"13","author":[{"given":"Vincent","family":"Pavot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7446-0443","authenticated-orcid":false,"given":"Catherine","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5678-3583","authenticated-orcid":false,"given":"Michael","family":"Kishko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie G.","family":"Anosova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Tibbitts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Raillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylviane","family":"Gautheron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Gutzeit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-8424","authenticated-orcid":false,"given":"Marguerite","family":"Koutsoukos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman M.","family":"Chicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-598X","authenticated-orcid":false,"given":"Valerie","family":"Lecouturier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"29219_CR1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827.e819 (2020).","journal-title":"Cell"},{"key":"29219_CR2","unstructured":"Davies N. G., et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372, eabg3055 (2021)."},{"key":"29219_CR3","doi-asserted-by":"crossref","unstructured":"Frampton D., et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect. Dis., 21, 1246\u20131256 (2021).","DOI":"10.1016\/S1473-3099(21)00170-5"},{"key":"29219_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","volume":"592","author":"H Tegally","year":"2021","unstructured":"Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438\u2013443 (2021).","journal-title":"Nature"},{"key":"29219_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"29219_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"29219_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","volume":"27","author":"CK Wibmer","year":"2021","unstructured":"Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 27, 622\u2013625 (2021).","journal-title":"Nat. Med."},{"key":"29219_CR8","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJMc2102179","volume":"384","author":"K Wu","year":"2021","unstructured":"Wu, K. et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N. Engl. J. Med. 384, 1468\u20131470 (2021).","journal-title":"N. Engl. J. Med."},{"key":"29219_CR9","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1056\/NEJMc2102017","volume":"384","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum. N. Engl. J. Med. 384, 1466\u20131468 (2021).","journal-title":"N. Engl. J. Med."},{"key":"29219_CR10","doi-asserted-by":"crossref","unstructured":"Cameroni E., et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 602, 664\u2013670 (2021).","DOI":"10.1038\/s41586-021-04386-2"},{"key":"29219_CR11","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","volume":"384","author":"V Shinde","year":"2021","unstructured":"Shinde, V. et al. Efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1899\u20131909 (2021).","journal-title":"N. Engl. J. Med."},{"key":"29219_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMc2104974","volume":"385","author":"LJ Abu-Raddad","year":"2021","unstructured":"Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. 385, 187\u2013189 (2021).","journal-title":"N. Engl. J. Med."},{"key":"29219_CR13","doi-asserted-by":"crossref","unstructured":"Puranik A. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. MedRXiv, 10.1101\/2021.08.06.21261707 (2021).","DOI":"10.1101\/2021.08.06.21261707"},{"key":"29219_CR14","unstructured":"Moderna. Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specic Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant. Press Release (10 March 2022)."},{"key":"29219_CR15","unstructured":"Pfizer. Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age. Press Release (25 January 2022)."},{"key":"29219_CR16","doi-asserted-by":"publisher","unstructured":"Matthew Gagne J. I. M., et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron. bioRxiv, https:\/\/doi.org\/10.1101\/2022.02.03.479037 (2022).","DOI":"10.1101\/2022.02.03.479037"},{"key":"29219_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1586\/erv.11.192","volume":"11","author":"N Vaughn","year":"2012","unstructured":"Gar\u00e7on, Vaughn, N. & Didierlaurent, D. W. AM. Development and evaluation of AS03, an Adjuvant System containing \u03b1-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines 11, 349\u2013366 (2012).","journal-title":"Expert Rev. Vaccines"},{"key":"29219_CR18","doi-asserted-by":"publisher","first-page":"17957","DOI":"10.1073\/pnas.1906613117","volume":"117","author":"AH Ellebedy","year":"2020","unstructured":"Ellebedy, A. H. et al. Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans. Proc. Natl Acad. Sci. USA 117, 17957\u201317964 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"29219_CR19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","volume":"370","author":"I Leroux-Roels","year":"2007","unstructured":"Leroux-Roels, I. et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370, 580\u2013589 (2007).","journal-title":"Lancet"},{"key":"29219_CR20","unstructured":"Francica J. R., et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci. Transl. Med., 13, eabi4547 (2021)."},{"key":"29219_CR21","doi-asserted-by":"publisher","unstructured":"Sridhar S., et al. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Lancet Infect. Dis., https:\/\/doi.org\/10.1016\/S1473-3099(21)00764-7 (2022).","DOI":"10.1016\/S1473-3099(21)00764-7"},{"key":"29219_CR22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1098\/rstb.2004.1490","volume":"359","author":"RM Anderson","year":"2004","unstructured":"Anderson, R. M. et al. Epidemiology, transmission dynamics and control of SARS: the 2002\u20132003 epidemic. Philos. Trans. R. Soc. Lond. B Biol. Sci. 359, 1091\u20131105 (2004).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"29219_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cell.2021.12.002","volume":"185","author":"M Gagne","year":"2022","unstructured":"Gagne, M. et al. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. Cell 185, 113\u2013130.e115 (2022).","journal-title":"Cell"},{"key":"29219_CR24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/infdis\/jiu284","volume":"210","author":"S Roy-Ghanta","year":"2014","unstructured":"Roy-Ghanta, S., Van der Most, R., Li, P. & Vaughn, D. W. Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study. J. Infect. Dis. 210, 1419\u20131430 (2014).","journal-title":"J. Infect. Dis."},{"key":"29219_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0076-2","volume":"3","author":"S Khurana","year":"2018","unstructured":"Khurana, S. et al. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. NPJ Vaccines 3, 40 (2018).","journal-title":"NPJ Vaccines"},{"key":"29219_CR26","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/infdis\/jiz295","volume":"220","author":"W Zhong","year":"2019","unstructured":"Zhong, W. & Levine, M. Z. Stockpiled avian influenza A(H7N9) vaccines induce robust, nonneutralizing functional antibodies against antigenically drifted fifth-wave A(H7N9) viruses. J. Infect. Dis. 220, 1276\u20131280 (2019).","journal-title":"J. Infect. Dis."},{"key":"29219_CR27","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.abl8912","volume":"374","author":"KS Corbett","year":"2021","unstructured":"Corbett, K. S. et al. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Science 374, 1343\u20131353 (2021).","journal-title":"Science"},{"key":"29219_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/imr.12640","volume":"283","author":"T Inoue","year":"2018","unstructured":"Inoue, T., Moran, I., Shinnakasu, R., Phan, T. G. & Kurosaki, T. Generation of memory B cells and their reactivation. Immunol. Rev. 283, 138\u2013149 (2018).","journal-title":"Immunol. Rev."},{"key":"29219_CR29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"29219_CR30","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/S0140-6736(21)00782-0","volume":"397","author":"F Krammer","year":"2021","unstructured":"Krammer, F. Correlates of protection from SARS-CoV-2 infection. Lancet 397, 1421\u20131423 (2021).","journal-title":"Lancet"},{"key":"29219_CR31","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"29219_CR32","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 383, 1544\u20131555 (2020).","journal-title":"N. Engl. J. Med."},{"key":"29219_CR33","unstructured":"Sanofi. Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2021\/2021-12-15-07-30-00-2352255. Press Release, (15 December 2021)."},{"key":"29219_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00324-5","volume":"6","author":"KV Kalnin","year":"2021","unstructured":"Kalnin, K. V. et al. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. NPJ Vaccines 6, 61 (2021).","journal-title":"NPJ Vaccines"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29219-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29219-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29219-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:48:59Z","timestamp":1669290539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29219-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["29219"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-29219-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-871537\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"3 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have declared the following interests: C.B., V.P., M.K., D.H., N.A., T.T., A.R., S.G., V.L., and R.C. are Sanofi employees and may own Sanofi shares. M.K. and C.G. are employees of the GSK group of companies and report ownership of GSK shares.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1699"}}